Education
About Us
Working with TipRanks
Follow Us
Oncopeptides AB (SE:ONCO)
:ONCO
ONCO Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr1.10 - kr3.23
Previous CloseN/A
Volume80.98K
Average Volume (3M)664.85K
Market Cap
kr310.56M
Enterprise Valuekr377.92M
Total Cash (Recent Filing)kr178.54M
Total Debt (Recent Filing)kr121.89M
Price to Earnings (P/E)―
Beta-0.19
Next Earnings
Aug 21, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding211,263,900
10 Day Avg. Volume862,664
30 Day Avg. Volume664,849
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.42
Price to Sales (P/S)0.00
P/FCF Ratio-1.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Oncopeptides AB News
PremiumCompany Announcements
Oncopeptides Initiates Real-World Study of Pepaxti in Spain
PremiumCompany Announcements
Oncopeptides AB Reports Strong Q1 2025 Growth and Strategic Advances
PremiumCompany Announcements
Oncopeptides AB to Release Q1 2025 Financial ReportOptions Prices
Currently, No data available
---
Ownership Overview
0.66% Insiders
―
Mutual Funds
― Other Institutional Investors
99.34% Public Companies and
Individual Investors
ONCO FAQ
What was Oncopeptides AB’s price range in the past 12 months?
Oncopeptides AB lowest stock price was kr1.10 and its highest was kr3.23 in the past 12 months.
What is Oncopeptides AB’s market cap?
Oncopeptides AB’s market cap is kr310.56M.
When is Oncopeptides AB’s upcoming earnings report date?
Oncopeptides AB’s upcoming earnings report date is Aug 21, 2025 which is in 65 days.
How were Oncopeptides AB’s earnings last quarter?
Oncopeptides AB released its earnings results on May 15, 2025. The company reported -kr0.287 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.287.
Is Oncopeptides AB overvalued?
According to Wall Street analysts Oncopeptides AB’s price is currently Overvalued.
Does Oncopeptides AB pay dividends?
Oncopeptides AB does not currently pay dividends.
What is Oncopeptides AB’s EPS estimate?
Oncopeptides AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncopeptides AB have?
Oncopeptides AB has 211,263,900 shares outstanding.
What happened to Oncopeptides AB’s price movement after its last earnings report?
Oncopeptides AB reported an EPS of -kr0.287 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.465%.
Which hedge fund is a major shareholder of Oncopeptides AB?
Currently, no hedge funds are holding shares in SE:ONCO
Company Description
Oncopeptides AB
Oncopeptides AB is a Sweden-based pharmaceutical company that focuses on the development of therapies for difficult-to-treat hematological diseases. The company's core product is melflufen (INN melphalan flufenamide), a peptide-drug conjugate intended for the treatment of multiple myeloma, which is a type of blood cancer. Oncopeptides leverages its proprietary Peptide-Drug Conjugate technology to deliver targeted treatments that improve the lives of patients with rare and hard-to-treat disorders.
Technical Analysis
Cantargia AB
―
Guard Therapeutics International AB
―
Immunicum AB
―
Isofol Medical AB
―
Xbrane Biopharma AB
―